Increased platelet responsiveness following coronary stenting: Heparin as a possible aetiological factor in stent thrombosis

European Heart Journal

Volumn 19, Issue 8, 1998, Pages 1239-1248

  Knight, C J ^a   Panesar, M ^b   Wilson, D J ^b   Patrineli, A ^b   Chronos, N ^a   Wright, C ^a   Clarke, D ^a   Patel, D ^a   Fox, K ^a   Goodall, Alison H ^b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Angioplasty; Heparin; Platelets; Stents

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; THROMBIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; BLOOD; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; FEMALE; HEPARINIZATION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECURRENT DISEASE; STENT; THROMBOCYTE ACTIVATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0032147003     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1047     Document Type: Article

References (40)

1. [1] Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up of a self-expanding coronary-artery stent. N Engl J Med 1991; 324: 13-17.
2. [2] Columbo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-88.
3. [3] Schomig A, Neumann F-J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
4. [4] Leon MB, Baim DS, Gordon P et al. Clinical and angiographic results from the Stent Anticoagulation Regimen Study (STARS) (Abstr). Circulation 1996; 94 (suppl I): I-685.
5. [5] Serruys PW, Strauss BH, van Beusekom H, van der Giessen WJ. Stenting of coronary arteries: has a modern Pandora's box been opened? J Am Coll Cardiol 1991; 17: 143B-54.
6. [6] Stevens DE, Joist JH, Sutera SP. Role of platelet-prostaglandin synthesis in shear-induced platelet alterations. Blood 1980; 56: 753-8.
7. [7] Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arteroscl Throm 1993; 13: 393-7.
8. [8] Eika C. Platelet refractory state induced by heparin. Scand J Haematol 1972; 9:665-72.
9. [9] Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
10. [10] Mikhailidis DP, Fonseca VA, Barradas MA, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmac 1987; 24: 415-24.
11. [11] Abrams CS, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemostas 1991; 65: 467-73.
12. [12] Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
13. [13] Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. Br J Haematol 1990; 76: 387-94.
14. [14] Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen in normal subjects and patients with activated platelets. Thromb Haemostas 1993; 70: 659-66.
15. [15] Mc Ever RP. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem 1991; 45: 156-61.
16. [16] Bratt G, Tornebohm E, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620.
17. [17] Goodall AH. Platelet activation during perparation and storage of concentrates: detection by flow cytometry. Blood Coag Fibrinolysis 1991; 21: 377-89.
18. [18] Golding JW.Monoclonal antibodies: principles and practice. London: Academic Press, 1986.
19. [19] Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD. Effect of strenuous exercise on platelet activation state and reactivity. Circulation 1993; 88: 1502-1.
20. [20] Janes SL, Kyle PM, Redman C, Goodall AH. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Thromb Haemostas 1995; 74: 1059-63.
21. [21] Hjemdahl P, Chronos NAF, Wilson DJ, Bouloux P, Goodall AH. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb 1994; 14: 77-84.
22. [22] Knight CJ, Pansesar M, Wilson DJ et al. Different effects of calcium antagonists, nitrates and betablockers on platelet function: possible importance for the treatment of unstable angina. Circulation 1997; 95: 125-32.
23. [23] Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Arterioscl Thromb 1992; 12: 1475-87.
24. [24] Langford EJ, Brown AS, Wainwright RJ et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994; 344: 1458-60.
25. [25] Chronos NA, Patel DJ, Sigwart U, Buller NP, Goodall AH. Intracoronary activation of human platelets following balloon angioplasty despite aspirin and heparin: a flow cytometric study (Abstr). Circulation 1994; 19: I-181.
26. [26] Kolarov P, Tschoepe D, Niewwnhuis HK, Gries FA, Strauer B, Schultheiss HP. PTCA: Periprocedural platelet activation. Part II of the Dusseldorf PTCA Platelet Study (DPPS). Eur Heart J 1996; 17: 1216-22.
27. [27] Gawaz M, Neumann F-J, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37.
28. [28] Chronos NAF, Goodall AH, Wilson DJ, Sigwart U, Buller NP. Profound platelet degranulation is an important side effect of some types of contrast media used in intervenional cardiology. Circulation 1993; 88: 2035-44.
29. [29] Brace LD, Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Seminars Thromb Haemostas 1985; 11: 190-8.
30. [30] Mirshahi M, Soria J, Neuhart E, Steg PG, Jacob P, Combe S, Soria C. Effect of heparin and enoxaparin on platelet interaction with fibrin clots. Thromb Res 1992; 65: 187-91.
31. [31] Kestin AS, Valeri R, Khuri SF et al. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107-17.
32. [32] Mohammed SF, Anderson WH, Smith JB, Chuang HYK, Mason RG. Effects of heparin on platelet aggregation and release and thromboxane A2 production. Am J Path 1981; 104: 132-41.
33. [33] Brace LD, Issleib S, Fareed J. Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. Thromb Res 1985; 39: 533-9.
34. [34] MacIntyre DE, Handin RI, Rosenberg R, Salzman EW. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation. Thromb Res 1981; 22: 167-75.
35. [35] Eldor A, Weksler BB. Heparin and dextran sulphate antagonize PGI2 inhibition of platelet aggregation. Thromb Res 1979; 16: 617-28.
36. [36] Upchurch GR, Freedman JE, Zhang Y, Welch GN, Loscalzo J. Heparin reverses the antiplatelet effect of nitric oxide. J Am Coll Cardiol 1996; 27 (Suppl A): 164A.
37. [37] Home III MK, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990; 74: 306-12.
38. [38] Mikhailidis, Holmer E, Lindahl E et al. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-69.
39. [39] Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 1986; 42: 435-47.
40. [40] Hafner G, Rupprecht HJ, Luz M et al. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.Eur Heart J 1996; 17: 1207-15.